Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. - Wikidata - wikimedia - TriplyDB

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

http://www.wikidata.org/entity/Q33848866

about

Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects.Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model.

P2860

Q47578122-D663F212-D9C3-4892-ADFE-5C3564105391 Q47981879-29E7A792-D1DC-467C-9C64-542CB46F1152 Q55451223-CD703801-19C0-490E-BE90-0BD203295F51

P2860

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

http://www.wikidata.org/entity/Q33848866

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

@ast

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

@en

type

label

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

@ast

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

@en

prefLabel

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

@ast

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

@en

P1433

Q33848866-CF16E45E-3F0E-4348-9570-EB2B11B5C940

P1476

Q33848866-483F7D6B-04F1-498B-880C-B23ADC5723CD

P2093

Q33848866-08CE1E28-EFEE-4FE2-9D06-CBEC01C2505A

Q33848866-3650B7DC-11B9-4C99-A005-8463ABF81916

Q33848866-5D24CEEB-E61A-4DC1-8ADD-A887722DD617

Q33848866-5F35C606-AA76-45D3-8195-637234DDDDD4

Q33848866-69892AD9-38DB-4051-BE0F-CC64AFAB639C

Q33848866-737ED5DC-3686-4508-B94F-FFAD0E271C3A

Q33848866-94458145-4AAF-48E1-9B85-CE76CBF9A746

Q33848866-B50B53C0-AE15-41CE-B895-C883468D1811

Q33848866-C2387BA9-021F-4515-8AC7-3DE5EE7698AC

Q33848866-FEF0BFBE-F336-4688-97F3-CACA38AFE7E5

P2860

Q33848866-10461D9D-38E7-4998-938A-1E0145578D21

Q33848866-16684BD6-52D8-4699-95F7-B8A7335FEE1E

Q33848866-2151D797-8078-47DD-BADA-C608AEFBB0F5

Q33848866-24ABF79D-C20F-4777-BA5B-6D08FFA9BB17

Q33848866-25E3A325-D8E5-4B8D-98F0-CC1DD6BC1012

Q33848866-297429B0-258A-4FC6-8F6C-61DE7A7641FC

Q33848866-3389AC82-413C-4F5D-B792-9C64B53FBDC7

Q33848866-5661C5BC-9D6C-4EA6-AE1C-8813603B3D3E

Q33848866-5D7EF85D-6228-45C8-8F6A-23B873AD8731

Q33848866-5F806F91-538A-4175-8E5F-F6AD92F55583

P304

Q33848866-F0DD310D-7268-4B09-BC65-22ED8C09967B

P31

Q33848866-0C1FC8B5-3AE7-4F15-9F29-148E7F11E262

P356

Q33848866-05302E9A-5767-4F19-BAF9-575C91732BD2

P433

Q33848866-43C84546-5A2D-4DF7-9711-CA911DDDA060

P478

Q33848866-1F6E57E4-2899-4990-9E63-A5BC7CC40929

P50

Q33848866-9047936F-CA09-409E-980B-D45327132294

P577

Q33848866-38E0542B-FB7A-483F-8968-0CE39298D0CC

P698

Q33848866-82AB0A00-589E-4181-AF09-32C6C3A814A1

P932

Q33848866-7DCB74EF-AC19-461E-BAE6-6DD8582ECC9D

P356

NXI.0000000000000374

P1433

Neurology(R) neuroimmunology & neuroinflammation

P1476

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

@en

P2093

Charles Murchison

http://www.w3.org/2001/XMLSchema#string

Dennis Bourdette

http://www.w3.org/2001/XMLSchema#string

Ed Kim

http://www.w3.org/2001/XMLSchema#string

Elizabeth Heriza

http://www.w3.org/2001/XMLSchema#string

Fay Horak

http://www.w3.org/2001/XMLSchema#string

Jack Simon

http://www.w3.org/2001/XMLSchema#string

Katherine Powers

http://www.w3.org/2001/XMLSchema#string

Michelle Cameron

http://www.w3.org/2001/XMLSchema#string

Rebecca Spain

http://www.w3.org/2001/XMLSchema#string

Vijayshree Yadav

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

A simple practice guide for dose conversion between animals and human

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

Advances in functional and structural MR image analysis and implementation as FSL

CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis.

Cap-independent Nrf2 translation is part of a lipoic acid-stimulated detoxification stress response

A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions.

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.

P304

e374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/NXI.0000000000000374

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Kimberly M Winges

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28680916

http://www.w3.org/2001/XMLSchema#string

P932

5489387

http://www.w3.org/2001/XMLSchema#string